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ABSTRACT
OBJECTIVE
To assess the association between learning disability 
and risk of hospital admission and death from 
covid-19 in England among adults and children.
DESIGN
Population based cohort study on behalf of NHS 
England using the OpenSAFELY platform.
SETTING
Patient level data were obtained for more than 17 
million people registered with a general practice in 
England that uses TPP software. Electronic health 
records were linked with death data from the Office for 
National Statistics and hospital admission data from 
NHS Secondary Uses Service.
PARTICIPANTS
Adults (aged 16-105 years) and children (<16 years) 
from two cohorts: wave 1 (registered with a TPP 
practice as of 1 March 2020 and followed until 31 
August 2020); and wave 2 (registered 1 September 
2020 and followed until 8 February 2021). The main 
exposure group consisted of people on a general 
practice learning disability register; a subgroup was 
defined as those having profound or severe learning 
disability. People with Down’s syndrome and cerebral 
palsy were identified (whether or not they were on the 
learning disability register).
MAIN OUTCOME MEASURE
Covid-19 related hospital admission and covid-19 
related death. Non-covid-19 deaths were also explored.
RESULTS
For wave 1, 14 312 023 adults aged ≥16 years were 
included, and 90 307 (0.63%) were on the learning 
disability register. Among adults on the register, 538 
(0.6%) had a covid-19 related hospital admission; 
there were 222 (0.25%) covid-19 related deaths 
and 602 (0.7%) non-covid deaths. Among adults 
not on the register, 29 781 (0.2%) had a covid-19 
related hospital admission; there were 13 737 (0.1%) 
covid-19 related deaths and 69 837 (0.5%) non-
covid deaths. Wave 1 hazard ratios for adults on the 
learning disability register (adjusted for age, sex, 
ethnicity, and geographical location) were 5.3 (95% 
confidence interval 4.9 to 5.8) for covid-19 related 
hospital admission and 8.2 (7.2 to 9.4) for covid-19 
related death. Wave 2 produced similar estimates. 
Associations were stronger among those classified 
as having severe to profound learning disability, and 
among those in residential care. For both waves, 
Down’s syndrome and cerebral palsy were associated 
with increased hazards for both events; Down’s 
syndrome to a greater extent. Hazard ratios for non-
covid deaths followed similar patterns with weaker 
associations. Similar patterns of increased relative 
risk were seen for children, but covid-19 related 
deaths and hospital admissions were rare, reflecting 
low event rates among children.
CONCLUSIONS
People with learning disability have markedly increased 
risks of hospital admission and death from covid-19, 
over and above the risks observed for non-covid 
causes of death. Prompt access to covid-19 testing 
and healthcare is warranted for this vulnerable group, 
and prioritisation for covid-19 vaccination and other 
targeted preventive measures should be considered.
Introduction
Identifying high risk groups for severe outcomes from 
covid-19 is critically important for risk stratification, 
which informs vaccine prioritisation initiatives and 
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WHAT IS ALREADY KNOWN ON THIS TOPIC 
Emerging evidence has shown that people with learning disability are at higher 
risk from covid-19 related mortality compared with the general population
Existing studies on the association of learning disability with severe outcomes 
from covid-19 often adjusted for variables that might be partly a consequence of 
the learning disability, such as deprivation and comorbidities, which complicates 
interpretation of results
WHAT THIS STUDY ADDS
Adults with learning disability and those with Down’s syndrome or cerebral palsy 
have markedly increased risks of hospital admission and death from covid-19
Similar patterns were observed for children, but absolute risks of covid-19 
hospital admission and death were small
Prompt access to covid-19 testing and healthcare is warranted for this group, and 
prioritisation for covid-19 vaccination and other targeted preventive measures 
should be considered
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other targeted preventive measures. People with 
learning disability, who total more than one million 
people in England alone or 2% of the adult population, 
are one such vulnerable group.1 People with learning 
disability have a lower intellectual ability (usually 
IQ<70) and impaired social and adaptive functioning, 
with the onset in childhood. Learning disabilities are 
usually classified using a wide severity range (mild, 
moderate, severe, or profound), and consequently 
intensity of support needs differs widely.
As of February 2021, the Learning from Death 
Reviews programme reported that 1405 people 
with a learning disability had died from covid-19 
in England since February 2020.2 The true number 
is probably far higher because of gaps in learning 
disability registration. The latest estimates from 2015 
suggest that 23% of people with learning disability 
are included on the learning disability register.1 
Emerging evidence from the first wave of the covid-19 
pandemic in the United Kingdom showed that people 
with learning disability were at higher risk from 
mortality3-7 than people in the general population. For 
instance, the Oxford RCGP Research and Surveillance 
Centre sentinel network reported an odds ratio of 
1.96 (95% confidence interval 1.22 to 3.18) for 
mortality during the first wave of infection in the 
UK among people with learning disability compared 
with those without.4 People with Down’s syndrome 
might be at particularly high risk; an analysis of 
primary care data from eight million adults reported 
a hazard ratio of 10.4 (7.1 to 15.2) for covid-19 death 
associated with Down’s syndrome.8 However, existing 
studies on the association of learning disability with 
severe outcomes from covid-19 do not include the 
second wave of the pandemic. Additionally, these 
studies frequently adjusted for variables that might 
be partly a consequence of the learning disability, 
such as deprivation and comorbidities, complicating 
interpretation of the results.4 A lack of clarity also 
exists on the increased risk of covid-19 deaths among 
people with milder learning disability, and this aspect 
needs exploration.9
The higher risk of premature death among people 
with learning disability in England is well known1 10 
and triggered the establishment of general practice 
learning disability registers to allow for better provi-
sion of their healthcare. A number of mechanisms exist 
which could increase the risk of covid-19 mortality 
in this group. People with learning disability have a 
higher prevalence of covid-19 mortality risk factors, 
including obesity, diabetes, epilepsy, and poverty.11-13 
Medical conditions underlying the learning disability 
might confer additional risk; for instance, people 
with Down’s syndrome are more vulnerable to 
impaired cellular immunity, congenital heart disease, 
and respiratory conditions.14 15 Many people with 
learning disability in England live in residential care 
or supported accommodation, or receive community 
based social care16; therefore, they have frequent 
contact with carers and other care recipients, and 
face challenges in physical distancing. Difficulties 
understanding the protective measures needed, 
compounded by a lack of accessible information, 
further increase the vulnerability of this group to 
infection.17 Healthcare access and quality, including 
prevention and treatment, are frequently worse for 
people with learning disability, leading to avoidable 
deaths.10 Treatment failures,10 including do not 
resuscitate orders,18 might increase their risk of death 
once infected.
Until 24 February 2021, the national recommenda-
tions for prioritisation of covid-19 vaccination in 
England included all adults with cerebral palsy, severe 
to profound learning disability, Down’s syndrome, 
and the whole resident population in care settings 
where a high proportion of residents would be 
eligible for vaccination (for example, due to learning 
disability).19 20 This guidance means that not everyone 
on the learning disability register would be eligible for 
covid-19 vaccination, including people with mild to 
moderate learning disability from causes other than 
Down’s syndrome or cerebral palsy who are not living 
in residential care. This work was undertaken rapidly 
in response to an urgent need to inform policy making 
on vaccination prioritisation in the UK and elsewhere.
The aim of this study was to use linked electronic 
health records within the OpenSAFELY platform to 
rapidly describe the risk of covid-19 related hospital 
admissions and deaths among children and adults 
with learning disability in England compared with 
the general population. A subsidiary aim was to 
separate the risk by type of learning disability (severe 
to profound, cerebral palsy, Down’s syndrome, on the 
learning disability register), including people with 
learning disability not originally included in the first 




We performed two population based, observational 
cohort studies of patients in England using data within 
the OpenSAFELY platform.
Data
We used data from primary care linked to secondary 
care and mortality records in England. Records were 
linked to the NHS England inpatient activity datasets 
from Secondary Uses Service (SUS) data extracts, 
including data from inpatient activity datasets for 
determining covid-19 related hospital admissions.21 
Office for National Statistics (ONS) death data were 
used to determine covid-19 related deaths. The 
dataset analysed within OpenSAFELY is based on 
24 million people currently registered with general 
practice surgeries that use TPP SystmOne software—
approximately 40% of the population in England. 
All data are pseudonymised and include coded 
diagnoses (using Read version 3, CTV3 codes), drugs, 
and physiological parameters. No free text data are 
included. The OpenSAFELY platform is a new data 
source and validation studies are not yet available. 
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Other datasets based on primary care records in 
England have been shown to have high validity.22
Study population
The first cohort comprised male and female patients 
(aged ≤105 years) registered as of 1 March 2020 
in a general practice that uses the TPP system and 
followed until 31 August 2020. We excluded patients 
with missing age or a recorded age >105 years, 
missing sex, or missing postcode (from which much 
of the household and geographical information 
is calculated). Patients in the second cohort were 
similarly defined, but included those registered as 
of 1 September 2020 and followed until 8 February 
2021. Patients in the two cohorts might differ slightly 
due to patients leaving and joining TPP practices, and 
patients dying prior to the start of the second cohort. 
These two time periods correspond to the two main 
waves of covid-19 infection experienced in England 
during 2020.23 In particular, 1 September 2020 had 
the lowest daily number of covid-19 related deaths 
since the start of the pandemic.24
Exposures
All codelists used to define exposure groups are 
provided online, with links given in the supplementary 
appendix. The main exposure group comprised 
people on the learning disability register. This register 
contains a subset of people with learning disability; 
it is not a comprehensive list. However, the register 
provides a simple and practical means of identifying 
people for vaccine prioritisation or implementation of 
other public health measures. A subset of the codes 
used to define the learning disability register classified 
the learning disability as severe to profound, and were 
used to classify a subset of patients as having severe to 
profound learning disability.
Because a comprehensive indicator of residential 
care is lacking, those living in a household containing 
at least five people identified as being on the learning 
disability register were classed as being in residential 
care. Households were identified based on general 
practice registered addresses as of 1 February 2020, 
standardised and corrected using publicly available 
house sale data to remove registrations that are 
probably not current. We use the term residential 
care throughout, although we note that this includes 
a range of settings (care homes, educational settings, 
sheltered accommodation) and misclassification also 
probably exists. People with Down’s syndrome and 
cerebral palsy were identified based on general practice 
codes, which were reviewed by clinicians specialising 
in the care of people with learning disability (details in 
supplementary appendix).
Outcomes
The outcomes for this study are covid-19 related 
death (defined as a covid-19 ICD-10 (international 
classification of diseases, 10th revision) code of U07.1 
or U07.2 anywhere on the death certificate, determined 
from ONS death certificate data), and covid-19 related 
hospital admission (defined as admissions with any 
ICD-10 admission diagnosis, not restricted to primary 
diagnosis, of U07.1 or U07.2, determined from SUS 
data). People who had a covid-19 related hospital 
admission and then died contributed to both outcomes. 
An additional outcome of non-covid-19 death was also 
considered, determined from ONS death certificate 
data and excluding deaths classed as covid-19 related.
Covariates
Covariates included demographics (age, sex, ethnicity, 
and geographical area), which could act as potential 
confounders, and current deprivation (index of 
multiple deprivation) as a potential mediator. To 
consider mediation by physical comorbidities that are 
also indications for vaccination we included body mass 
index ≥40, chronic cardiac disease, atrial fibrillation, 
deep vein thrombosis or pulmonary embolism, 
diabetes (further grouped by level of control, as 
measured by the latest glycated haemoglobin (HbA1c) 
measurement or lack of a measurement), chronic liver 
disease, stroke, transient ischaemic attack, dementia, 
asthma requiring use of oral corticosteroids, other 
chronic respiratory disease, reduced kidney function, 
dialysis, organ transplant, asplenia, other conditions 
leading to immunosuppression, and haematological 
cancer. We also included non-haematological cancer 
diagnosed in the past year, rheumatoid arthritis or 
lupus or psoriasis, and inflammatory bowel disease as 
common indications for immunosuppressing drugs. 
These conditions aim to map to the existing physical 
indications for vaccination among people aged 16-64 
years in England; however data on epilepsy were not 
available for this analysis. We also identified other 
neurological conditions and serious mental illness to 
exclude people already prioritised for vaccination. We 
obtained these measures from medical records (details 
in supplementary appendix).
Statistical methods
Analysis was undertaken separately for adults aged 
≥16 years and children aged <16 years. We repeated 
analyses for the following exposures: being on the 
learning disability register (total, then divided into 
severe to profound v mild to moderate, and residential 
care v non-residential care), Down’s syndrome, and 
cerebral palsy.
The two cohorts for each wave were analysed 
separately. We used Cox proportional hazards for 
covid-19 related mortality and covid-19 related 
hospital admission, stratified by local geographical 
area as measured by the Sustainability and 
Transformation Partnership to account for differing 
patterns of infection over time in different regions, 
with days in study as the timescale. Follow-up was 
censored at competing events (non-covid death for 
mortality analyses and any cause death for hospital 
admission analyses) to target the cause specific hazard. 
Models adjusted for confounders (age, sex, ethnicity), 
additionally for deprivation, residential care status 
and physical comorbidities (described above), and 
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then adjusted for all of these factors simultaneously. 
We explored exposure interactions with broad age 
ranges (16-64, 65-74, ≥75), sex, and deprivation. Tests 
based on Schoenfeld residuals were used to assess the 
proportional hazards assumption.
Similar Cox models were fitted for covid-19 related 
hospital admissions, after excluding people who were 
already prioritised for vaccination because of age or 
comorbidities as part of the first six priority groups of 
phase 1 in the UK. These were people aged ≥65 years and 
people with codes for physical conditions indicating 
priority for vaccination, other neurological conditions, 
severe mental illness, Down’s syndrome, cerebral 
palsy, and severe to profound learning disability. 
These Cox models adjusted for the confounders, then 
separately for deprivation and residential care status. 
Finally, Cox models for non-covid deaths were fitted, 
adjusting for the same variables as previous models.
For children <16 years, these analyses were 
undertaken separately. We omitted analyses looking 
at death, full adjustment for comorbidities, and 
interaction analyses because of smaller numbers of 
outcomes.
Missing data
The main analysis took a complete case approach 
for missing ethnicity data (around 25% of records). 
Previous analyses using these data suggest the 
assumption required for complete case analysis for 
ethnicity—that missingness is unrelated to outcome 
given covariates—is approximately satisfied here.12
There were also missing data for body mass index, 
serum creatinine, and HbA1c measurements. For 
each of these variables, previous research into their 
recording in UK primary care records suggested that 
multiple imputation would not be appropriate because 
the assumption that the data are missing at random is 
not met: for example, people who are underweight and 
overweight will be more likely to have their body mass 
index recorded in primary care25; serum creatinine 
measurement typically reflects monitoring because of 
underlying risk factors for chronic kidney disease or a 
known diagnosis26; and social disparities in monitoring 
of HbA1c among people with diabetes.
27 People with 
missing body mass index were assumed to be non-
obese. People with no serum creatinine measurement 
were included in the category “no evidence of poor 
kidney function,” an approach which has been found 
to produce prevalence estimates of chronic kidney 
disease comparable to those from other sources.28 When 
categorising people with diabetes according to glycaemic 
control, those with no HbA1c measurement were included 
in a separate group “diabetes, no Hba1c” as an indicator 
for diabetes with poorly monitored glycaemic control.
We undertook two sensitivity analyses. Firstly, 
multiple imputation was performed, creating 10 
imputed datasets separately for adults and children, 
and imputing ethnicity using a multinomial regression 
model that included all covariates, outcome indicators, 
and a Nelson-Aalen estimate of the cumulative hazard 
in the imputation model. Estimates were combined by 
using Rubin’s rules. Secondly, a complete case analysis 
was performed discarding people with no body mass 
index measurement; when data are missing not at 
random, complete case analysis might be less biased 
than multiple imputation.29
Software and reproducibility
The prespecified study protocol is archived with version 
control (https://github.com/opensafely/Published-
Protocols/blob/master/Learning_Disability_Covid_
Protocol_2021_10_02.pdf). All code and codelist data 
are shared openly for review and reuse under the MIT 
open license (https://github.com/opensafely/absolute-
risks-covid-research, https://codelists.opensafely.
org/). The OpenSAFELY framework guarantees that 
the analytic code, clinical codelists, data processing 
logic, and all dependent libraries remain available and 
executable against randomly generated dummy data. 
The full analysis can be rerun against real data with 
one click by any person with the necessary information 
governance approvals.
Patient and public involvement
We have developed a publicly available website 
(https://opensafely.org/) through which we invite any 
patient or member of the public to contact us about 
this study or the broader OpenSAFELY project. We 
were not able to undertake extensive patient or public 
involvement during the short time frame for producing 
results. However, we did consult with three clinicians 
specialising in the care of people with learning 
disabilities. An online Health Protection Research 
Unit (HPRU) in Vaccines and Immunisation public 
engagement event in December 2020 discussing the 
use of pseudonymised medical records to investigate 
who is at higher risk of severe covid-19 found that this 
research approach was supported and expected as part 
of the pandemic response.
Results
Table 1 shows the baseline characteristics of people 
included in the analysis, given separately for those aged 
≥16 years and those aged <16 years (characteristics in 
wave 2 were similar). Figure A1 in the supplementary 
appendix shows a flowchart of participant numbers 
through the study selection process.
Among 14 312 023 adults aged ≥16 years, 90 307 
(0.63%) were identified as being on the learning 
disability register (table 1). The largest group consisted 
of people with mild to moderate learning disability 
(74 116, 82%). Additionally, 16 191 (18%) were 
identified as having severe to profound learning 
disability, and 8033 (9%) as being in residential care. 
In total, 7990 adults were identified as having Down’s 
syndrome, of whom 7128 (89%) were on the learning 
disability register; 18 298 adults were identified as 
having cerebral palsy, of whom 6950 (38%) were on 
the learning disability register. Those on the learning 
disability register were more likely to be male, younger, 
and living in more deprived areas. Comorbidities were 
similar across groups; more people with diabetes, 
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Characteristics
Adults (≥16 years) Children (<16 years)
On learning  
disability register 
Not on learning  
disability register
On learning  
disability register
Not on learning  
disability register
Total 90 307 (100) 14 221 716 (100) 9298 (100) 2 617 720 (100)
Age group
 0-15 0 (0) 0 (0) 9298 (100) 2 617 720 (100)
 16-44 52 333 (58) 6 360 525 (45) 0 (0) 0 (0)
 45-64 29 114 (32) 4 633 383 (33) 0 (0) 0 (0)
 65-69 3870 (4) 889 199 (6) 0 (0) 0 (0)
 70-74 2704 (3) 894 793 (6) 0 (0) 0 (0)
 75-79 1371 (2) 622 787 (4) 0 (0) 0 (0)
 ≥80 915 (1) 821 029 (6) 0 (0) 0 (0)
Sex
 Female 36 801 (41) 7 356 253 (52) 3013 (32) 1 276 612 (49)
 Male 53 506 (59) 6 865 463 (48) 6285 (68) 1 341 108 (51)
Ethnicity
 White 81 261 (90) 12 044 684 (85) 7120 (77) 2 071 494 (79)
 Black 1710 (2) 402 235 (3) 379 (4) 96 181 (4)
 South Asian 5499 (6) 1 179 377 (8) 1271 (14) 279 286 (11)
 Mixed 1125 (1) 206 860 (1) 307 (3) 99 517 (4)
 Other 712 (1) 388 560 (3) 221 (2) 71 242 (3)
Region
 East 18 479 (20) 3 280 536 (23) 1850 (20) 618 211 (24)
 London 3619 (4) 1 166 888 (8) 565 (6) 167 329 (6)
 Midlands 21 480 (24) 3 162 698 (22) 2202 (24) 609 609 (23)
 North East, Yorkshire, and The Humber 19 655 (22) 2 709 851 (19) 2071 (22) 493 405 (19)
 North West 10 228 (11) 1 243 972 (9) 981 (11) 224 084 (9)
 South East 5256 (6) 862 061 (6) 570 (6) 170 246 (7)
 South West 11 590 (13) 1 795 710 (13) 1059 (11) 334 836 (13)
Index of multiple deprivation
 1 (least deprived) 9719 (11) 2 804 359 (20) 1239 (13) 486 452 (19)
 2 13 589 (15) 2 850 388 (20) 1373 (15) 464 177 (18)
 3 17 339 (19) 2 910 085 (20) 1648 (18) 492 125 (19)
 4 21 635 (24) 2 877 452 (20) 2116 (23) 533 117 (20)
 5 (most deprived) 28 025 (31) 2 779 432 (20) 2922 (31) 641 849 (25)
Learning disability and related
 Mild-moderate learning disability 74 116 (82) — 7909 (85) —
 Severe-profound learning disability 16 191 (18) — 1389 (15) —
 Not in residential care* 82 274 (91) 14 220 351 (100) 9235 (99) 2 617 669 (100)
 Residential care* 8033 (9) 1365 (<1) 63 (1) 51 (<1)
 No Down’s syndrome 83 179 (92) 14 220 854 (100) 8387 (90) 2 615 994 (100)
 Down’s syndrome 7128 (8) 862 (<1) 911 (10) 1726 (<1)
 No cerebral palsy 83 357 (92) 14 210 368 (100) 8789 (95) 2 613 598 (100)
 Cerebral palsy 6950 (8) 11 348 (<1) 509 (5) 4122 (<1)
Comorbidities
 Body mass index≥40 5897 (7) 382 625 (3) 71 (1) 4412 (<1)
 Asthma (with OCS use) 879 (1) 129 455 (1) — —
 Cystic fibrosis 35 (<1) 3731 (<1) — —
 Respiratory disease 3521 (4) 574 387 (4) — —
 Chronic cardiac disease 5637 (6) 915 988 (6) — —
 Atrial fibrillation 2311 (3) 507 890 (4) — —
 Deep vein thrombosis or pulmonary embolism 2072 (2) 291 929 (2) — —
 Diabetes
  With HbA1c <58 mmol/mol 6793 (8) 855 216 (6) — —
  With HbA1c ≥58 mmol/mol 3417 (4) 401 014 (3) — —
  With no recent HbA1c measure 1324 (1) 160 068 (1) — —
 Liver disease 459 (1) 85 620 (1) — —
 Stroke 1966 (2) 287 098 (2) — —
 Transient ischaemic attack 931 (1) 217 105 (2) — —
 Dementia 1887 (2) 169 050 (1) — —
 Other neurological disease 8857 (10) 129 745 (1) — —
 Poor kidney function
  Stage 3a/3b, eGFR 30-60 2817 (3) 714 502 (5) — —
  Stage 4/5, eGFR <30 518 (1) 68 534 (<1) — —
 Dysplenia 141 (<1) 23 082 (<1) — —
 Organ transplant 191 (<1) 12 990 (<1) — —
 Conditions leading to immunosuppression 484 (1) 40 802 (<1) — —
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obesity, other neurological disease, and diagnoses 
of serious mental illness were among those on the 
learning disability register.
Among 2 627 018 children aged <16 years (table 1), 
9298 (0.35%) were identified as being on the learning 
disability register. Of the 2637 children identified as 
having Down’s syndrome, only 911 (35%) were on 
the learning disability register. Of the 4631 children 
identified as having cerebral palsy, 509 (11%) were on 
the learning disability register.
Covid-19 related hospital admissions and deaths 
among adults ≥16 years
Adults aged ≥16 years were followed up for 7.1 million 
person years (mean 0.5 years per person) during wave 
1 (1 March 2020-31 August 2020; 183 days). Among 
adults on the learning disability register, 538 (0.6%) 
had a covid-19 related hospital admission; there 
were 222 (0.25%) covid-19 related deaths and 602 
(0.7%) non-covid deaths. Among adults not on the 
register, 29 781 (0.2%) had a covid-19 related hospital 
admission; there were 13 737 (0.1%) covid-19 related 
deaths and 69 837 (0.5%) non-covid deaths.
Adults were followed up for 6.3 million person 
years (mean 0.4 years per person) during wave 2 (1 
September 2020-8 February 2021; 160 days). Among 
91 358 adults on the learning disability register, 1004 
(1.1%) had a covid-19 related hospital admission; 
there were 286 (0.3%) covid-19 related deaths and 524 
(0.6%) non-covid deaths. Among 14 260 586 adults not 
on the register, 63 053 (0.4%) had a covid-19 related 
hospital admission; there were 19 778 (0.1%) covid-19 
related deaths and 58 021 (0.4%) non-covid deaths.
Figure 1 shows cumulative covid-19 related deaths 
and hospital admissions among adults during the 
study period, accounting for sex, age, and ethnicity for 
people on the learning disability register and those who 
were not. Both graphs show a clear increase in events 
among those on the learning disability register, with 
a flattening off apparent during the period between 
waves of infection.
Covid-19 related hospital admissions and deaths 
among children <16 years
Among children <16 years, 286 covid-19 related hospital 
admissions occurred in wave 1 during 1.3 million 
person years of follow-up (mean 0.5 years per person) 
and 529 in wave 2 during 1.1 million person years of 
follow-up (mean 0.4 years per person). Among 9298 
children on the learning disability register during wave 
1, there were five or fewer (≤0.05%) covid-19 related 
hospital admissions; we cannot provide the exact 
number because of stringent redaction rules applied 
to protect patient privacy. Among 9429 children on 
the learning disability register during wave 2, there 
were 20 (0.2%) covid-19 related hospital admissions. 
In total, across both waves, there were nine non-covid 
deaths among children on the register and 151 non-
covid deaths among children not on the register. For 
covid-19 related deaths, there were five or fewer among 
children on the register and five or fewer among those 
not on the register. The number of deaths classed as 
covid-19 related was low among children overall.
Hazard ratios for covid-19 hospital admissions and 
deaths among adults ≥16 years
For wave 1, the estimated hazard ratio for covid-19 
related hospital admission among adults on the 
learning disability register (adjusted for age, sex, 
ethnicity, and geographical location) was 5.3 (95% 
confidence interval 4.9 to 5.8; table 2). The hazard 
ratio for covid-19 related death was 8.2 (7.2 to 9.4). 
Wave 2 produced similar estimates (4.3, 4.1 to 4.6 for 
covid-19 related hospital admission; 7.2, 6.4 to 8.1 
for covid-19 related death). These associations were 
stronger among those with learning disability classed 
as severe to profound and among those in residential 
care. Down’s syndrome was associated with increased 
hazard of both events in both waves (wave 1: 10.6, 
8.5 to 13.2 for covid-19 related hospital admission; 
36.3, 26.7 to 49.5 for covid-19 related death; similar 
numbers were found for wave 2). Cerebral palsy was 
associated with higher hazards but to a lesser extent 
(wave 1: 5.0, 3.9 to 6.4 for covid-19 related hospital 
admission; 5.8, 4.1 to 8.3 for covid-19 related death; 
similar numbers were found for wave 2).
Further adjustment for deprivation, residential care, 
and physical comorbidities only slightly attenuated 
these associations (supplementary appendix). For 
wave 1, the confounder adjusted hazard ratio for 
covid-19 related hospital admission for those on the 
learning disability register was 5.3 (95% confidence 
Characteristics
Adults (≥16 years) Children (<16 years)
On learning  
disability register 
Not on learning  
disability register
On learning  
disability register
Not on learning  
disability register
 Haematological malignancy
  Diagnosed in past year 25 (<1) 7138 (<1) — —
  Diagnosed 2-5 years ago 80 (<1) 21 673 (<1) — —
  Diagnosed >5 years ago 283 (<1) 49 569 (<1) — —
 Cancer (non-haematological) in past year 196 (<1) 63 011 (<1) — —
 RA/SLE/psoriasis 4277 (5) 710 575 (5) — —
 Inflammatory bowel disease 871 (1) 178 869 (1) — —
 Serious mental illness 8026 (9) 168 342 (1) — —
eGFR=estimated glomerular filtration rate; HbA1c=glycated haemoglobin; OCS=oral corticosteroid; RA=rheumatoid arthritis; SLE=systemic lupus 
erythematosus.
*Living in household containing at least five people identified as being on learning disability register.
Table 1 | Continued
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interval 4.9 to 5.8), reducing to 3.9 (3.6 to 4.3) after 
full adjustment. However, for Down’s syndrome, 
adjustment for residential care and comorbidities 
greatly attenuated hazard ratios (for example, the wave 
1 hazard ratio for covid-19 related hospital admission 
reduced from 10.6 (8.5 to 13.2) to 6.4 (4.9 to 8.3) after 
adjustment for residential care, 7.2 (5.8 to 9.0) after 
adjustment for physical comorbidities, and 4.7 (3.6 to 
6.0) after adjustment for all factors.
Tests of the proportional hazards assumption 
showed some evidence of non-proportionality (P 
values <0.001 for covid-19 related death and 0.176 
for covid-19 related hospital admission in wave 1; 
corresponding values for wave 2 were 0.12 and 0.09, 
respectively). Therefore, the results reflect average 
hazard ratios over the follow-up periods.
Hazard ratios for covid-19 hospital admission 
among children <16 years
Among children <16 years, being on the learning 
disability register was associated with increased 
hazard of covid-19 related hospital admission (wave 1: 
hazard ratio 6.2, 95% confidence interval 2.8 to 14.1; 
wave 2: 9.2, 5.9 to 14.3).
Effect modification among adults ≥16 years
In wave 1, an interaction was observed between age 
and being on the learning disability register on the 
hazard of covid-19 related death: hazard ratio for 
being on the learning disability register 12.3, 95% 
confidence interval 10.0 to 15.1 for people aged 
16-64; 10.5, 8.3 to 13.2 for people aged 65-74; and 
4.2, 3.2 to 5.5 for people aged ≥75; similar estimates 
were observed for wave 2 (supplementary appendix). 
A similar interaction was not observed for covid-19 
related hospital admission in waves 1 or 2. No 
interaction was observed by sex. Larger hazard ratios 
for covid-19 related hospital admission and death were 
observed for adults living in the least deprived areas 
compared with those in the more deprived areas, with 
similar patterns seen in both waves. Insufficient data 
were available to explore interactions by ethnicity.
Hazard ratios among adults ≥16 years not 
prioritised for vaccination
After excluding people aged ≥65 years and those 
with defined comorbidities, the estimated hazard of 
covid-19 related hospital admission was 4.1 (95% 
confidence interval 3.3 to 5.2) after adjustment for age, 
sex, ethnicity, and geographical location, with little 
change after adjustment for deprivation or residential 
care status. Slightly attenuated associations were seen 
in wave 2 (3.0, 2.5 to 3.5) after adjustment for age, sex, 
ethnicity, and geographical location.
Hazard ratios for non-covid death among adults ≥16 
years
The estimated hazard ratio for non-covid death 
among adults (adjusted for age, sex, ethnicity, and 
geographical location) was 3.7 (95% confidence 
interval 3.4 to 4.0) in wave 1 and 4.0 (3.7 to 4.3) in 
wave 2. Associations were stronger among those 
classed as having severe to profound learning 
disability. Associations were slightly stronger among 
those classed as being in residential care. Down’s 
syndrome was associated with an increased hazard 
of non-covid death (wave 1: 12.3, 9.9 to 15.1; similar 
numbers were observed for wave 2). Cerebral palsy was 
associated with higher hazards to a lesser extent (wave 
1: 3.2, 2.6 to 3.9 for covid-19 related death; similar 
numbers were observed for wave 2).
Sensitivity analyses for missing data
Before excluding those with missing ethnicity data 
in wave 1, missing data occurred in 6 706 630 (28%) 
people for ethnicity, 7 027 371 (30%) for body mass 
index, and 221 283 (12% of 1 643 973 people with 
diabetes) for HbA1c. The measurement of serum 
creatinine typically reflects monitoring because of 
underlying risk factors for chronic kidney disease or 
a known diagnosis, reflected in approximately half 
of the sample (11 315 631, 48%) not having a serum 
creatinine measurement in the past five years. Wave 2 
numbers were similar.
For adults, multiple imputation for missing 
ethnicity data made little difference to the results 
(supplementary appendix). When we analysed only 
people with recorded body mass index, the hazard 
ratios were slightly attenuated, but the pattern 
remained similar. For children, hazard ratios were 
slightly attenuated in wave 1 but similar in wave 2 
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Fig 1 | Cumulative covid-19 related deaths, and covid-19 related hospital admissions 
and deaths with 95% confidence intervals for adults aged ≥16 years through two waves 
of infection. People on learning disability register and those not on register shown 
separately. Estimates are standardised by age, sex, and ethnicity
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missing ethnicity data. Overall, our conclusions were 
robust to the method used to address missing data.
Discussion
Our data show higher risk of hospital admission and 
death for all groups with learning disability compared 
with the general population. Generally, the pattern 
of hazard ratios is consistent for waves 1 and 2. For 
hospital admissions and deaths, slightly weaker 
associations were observed for wave 2 than for wave 1. 
Additionally, we found higher risks among those with 
severe to profound learning disability compared with 
those with mild to moderate learning disability, which 
was not explained by measured physical comorbidities 
or residential care status. However, the absolute 
number of deaths was higher among people with mild 
to moderate learning disability. 
For patients with Down’s syndrome or cerebral 
palsy, we observed higher risks among those on the 
learning disability register. Higher risks remained 
among those on the learning disability register who do 
not have Down’s syndrome or cerebral palsy compared 
with the general population. This observation is 
not explained by measured physical comorbidities 
or residential care status. After we excluded people 
who were prioritised for vaccination (first six groups 
of the phase 1 vaccination priority list in England 
due to age or comorbidities), those on the learning 
disability register still had a substantially increased 
risk of covid-19 related hospital admission. We also 
observed a higher risk of non-covid deaths in people 
with learning disability, though associations were 
weaker than for covid-19 related deaths. This finding 
is in contrast to most other risk factors that appear to 
have a similar magnitude of association with covid-19 
related deaths and non-covid deaths.30
Findings in context
Our findings are consistent with the existing literature, 
yet make an important contribution by including 
outcomes from the second wave of the pandemic 
and by showing the importance of the learning 
disability register in identifying people for vaccination 
prioritisation. The Oxford RCGP Research and 
Surveillance Centre sentinel network, which includes 
4.4 million people who are nationally representative 
of the population in England, reported twofold higher 
mortality rates among people with learning disability 
(odds ratio 1.96, 95% confidence interval 1.22 to 
3.18, P<0.01) after extensive adjustment.4 Public 
Health England used different sources of data and 
estimated that, up to June 2020, the mortality rate 
in people with learning disability was approximately 
6.3-fold higher than that of the general population.31 
Data from Scotland also showed that adults with 
intellectual disabilities had higher rates of covid-19 
infection, severe infection, and mortality.5 Increased 
risks remained after adjusting for age, sex, and 
deprivation (standardised severe infection ratio: 2.59, 
95% confidence interval 1.80 to 3.39; standardised 
mortality ratio 3.20, 2.1 to 4.25). Higher mortality 
rates among people with learning disability have also 
been reported in Wales,6 New York State,7 and the 
United States more broadly.3 Not only are death rates 
higher for people with learning disability, but deaths 
occur at younger ages.3 8 9 31 The increased mortality 
rates among younger people with learning disability 
observed in our study have also been reported in the 
US.3 The younger age at death among people with 
learning disability is also well established for non-
covid deaths.10
The high risk for people with Down’s syndrome 
was shown for the first wave by Clift and colleagues 
by using the QResearch population level primary care 
database8. In their cohort of eight million adults in 
England from January to June 2020, the age and sex 
adjusted hazard ratio for covid-19 death for adults 
with Down’s syndrome versus those without was 24.94 
(95% confidence interval 17.08 to 36.44), which 
reduced to 10.39 (7.08 to 15.23) after extensive adjust-
ment (deprivation, body mass index, cardiovascular, 
pulmonary and other disease, residential status, 
ethnicity). Data for cerebral palsy are more limited, but 
the QResearch analyses showed a higher mortality rate 
for this group (2.66, 1.62 to 4.36). Clift and colleagues 
obtained a fully adjusted hazard ratio of 1.27 (1.16 to 
1.40) for covid-19 related death in those with learning 
disabilities other than Down’s syndrome, in contrast 
to our higher estimates. This discrepancy is probably 
because of differences in adjustment. We chose not to 
adjust for many comorbidities, viewing most of them as 
consequences of the learning disability and therefore 
part of the causal pathway. In our analyses, children 
with learning disability had a higher risk of hospital 
admission for covid-19. Existing studies also indicate 
that children with learning disability are more likely 
to require hospital admission and critical care because 
of covid-19 outcomes.32-36 However, it is important to 
note that the absolute risk of covid-19 related hospital 
admission experienced by children on the learning 
disability register was low.
While the incompleteness of the learning disability 
register means we will not have captured all deaths 
among children with learning disability, among children 
on the learning disability register there were fewer 
than five deaths per 1000 children years in each wave. 
Evidence about the relative risk of covid-19 related 
mortality associated with learning disability is lacking 
for children. The reason for this evidence gap is the 
small risk experienced by children overall—in our 
cohorts, few covid-19 related deaths occurred in 
children and so there were not enough data to analyse. 
Therefore, while we cannot quantify any differences 
in risk of covid-19 related deaths in children on the 
learning disability register, the absolute risk remains low.
The hazard ratios for covid-19 outcomes in our 
study attenuated after adjustment for deprivation. 
Residential status also partially explained the higher 
risks of severe covid-19 outcomes in people with 
learning disability. However, residential care for people 
with learning disability might not raise risk as much as 
in other care settings, perhaps because these facilities 
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generally have fewer occupants.31 An important driver 
appears to be comorbidities, reflecting the higher 
prevalence of these covid-19 risk factors among people 
with learning disability.11 13 Comorbidities are also an 
important driver of increased risk of non-covid deaths.10 
However, large excess mortality rates remained 
after extensive adjustment, which is also apparent 
in previous studies.8 This pattern implies that other 
drivers might be relevant, including inherent clinical 
vulnerabilities for people with certain conditions and 
concerns about healthcare quality, as also indicated 
by the higher case fatality rates among people with 
learning disability (Scotland: 30% v 24%13; New York: 
15.0% v 7.9%7; US 18-74 year olds: 4.5% v 2.7%3). 
Additional mechanisms might contribute to the high 
risk among people with Down’s syndrome, including 
impaired cellular immunity.15
Strengths and weaknesses
Key strengths and weaknesses of the OpenSafely 
platform have been outlined previously.12 An important 
strength in the current analyses is that the study is 
large, including the records of approximately 40% of 
the English population, which allows disaggregation by 
learning disability grouping. We used comprehensive 
data on participants from medical records, which 
allowed us to adjust analyses successively to explore 
mechanisms for the association of learning disability 
and adverse covid-19 outcomes. Additionally, we 
were able to assess excess risks for both waves of the 
covid-19 pandemic, in terms of hospital admission and 
mortality outcomes. We also considered children and 
adults.
This study also has important limitations. Substantial 
geographical variation exists in the choice of electronic 
Table 2 | Estimated hazard ratios for covid-19 outcomes among adults ≥16 years and children <16 years adjusted for potential confounders (age, sex, 
ethnicity, geographical region)
Exposure category
Covid-19 related hospital admission Covid-19 related death
Events Person years Crude rate* (95% CI) Hazard ratio (95% CI) Events Person years Crude rate* (95% CI) Hazard ratio (95% CI)
Wave 1: adults (≥16 years)
Learning disability register
 No 29 781 7 133 803 4.2 (4.1 to 4.2) Reference 13 737 7 140 988 1.9 (1.9 to 2.0) Reference
 Yes 538 45 126 11.9 (11.0 to 13.0) 5.30 (4.85 to 5.80) 222 45 257 4.9 (4.3 to 5.6) 8.21 (7.15 to 9.42)
Severity (learning disability register)
 Mild 391 37 070 10.5 (9.6 to 11.6) 4.74 (4.30 to 5.23) 159 37 167 4.3 (3.7 to 5.0) 7.15 (6.12 to 8.34)
 Profound 147 8056 18.2 (15.5 to 21.4) 7.75 (6.43 to 9.33) 63 8090 7.8 (6.1 to 10.0) 13.14 (9.94 to 17.39)
Residential care status
 Not in residential care 438 41 141 10.6 (9.7 to 11.7) 4.87 (4.44 to 5.34) 182 41 249 4.4 (3.8 to 5.1) 7.81 (6.77 to 9.02)
 In residential care 100 3984 25.1 (20.6 to 30.5) 8.72 (6.77 to 11.25) 40 4008 10.0 (7.3 to 13.6) 10.65 (7.08 to 16.03)
Down’s syndrome
 No 30 244 7 174 961 4.2 (4.2 to 4.3) Reference 13 918 7 182 261 1.9 (1.9 to 2.0) Reference
 Yes 75 3968 18.9 (15.1 to 23.7) 10.59 (8.47 to 13.23) 41 3983 10.3 (7.6 to 14.0) 36.34 (26.67 to 49.51)
Cerebral palsy
 No 30 221 7 169 773 4.2 (4.2 to 4.3) Reference 13 929 7 177 063 1.9 (1.9 to 2.0) Reference
 Yes 98 9156 10.7 (8.8 to 13.0) 4.95 (3.86 to 6.36) 30 9181 3.3 (2.3 to 4.7) 5.83 (4.12 to 8.26)
Wave 1: children (<16 years)
Learning disability register
 No >200† 1 318 599 0.2 (0.2 to 0.2) Reference —‡ —‡ —‡ —‡
 Yes ≥5† 4700† 1.1 (0.4 to 2.6) 6.21 (2.75 to 14.05) —‡ —‡ —‡ —‡
Wave 2: adults (≥16 years)
Learning disability register
 No 63 053 6 262 945 10.1 (10.0 to 10.1) Reference 19 778 6 270 857 10.1 (10.0 to 10.1) Reference
 Yes 1004 40 002 25.1 (23.6 to 26.7) 4.32 (4.05 to 4.61) 286 40 121 25.1 (23.6 to 26.7) 7.22 (6.41 to 8.13)
Severity (learning disability register)
 Mild 722 32 856 22 (20.4 to 23.6) 3.82 (3.55 to 4.11) 197 32 943 22.0 (20.4 to 23.6) 6.07 (5.29 to 6.96)
 Profound 282 7146 39.5 (35.1 to 44.3) 6.52 (5.77 to 7.37) 89 7177 39.5 (35.1 to 44.3) 12.42 (10.06 to 15.33)
Residential care status
 Not in residential care 813 36 637 22.2 (20.7 to 23.8) 3.92 (3.64 to 4.21) 231 36 735 22.2 (20.7 to 23.8) 6.73 (5.91 to 7.66)
 In residential care 191 3365 56.8 (49.3 to 65.4) 7.73 (6.51 to 9.19) 55 3385 56.8 (49.3 to 65.4) 10.37 (7.61 to 14.12)
Down’s syndrome
 No 63 898 6 299 465 10.1 (10.1 to 10.2) Reference 19 998 6 307 480 10.1 (10.1 to 10.2) Reference
 Yes 159 3482 45.7 (39.1 to 53.3) 9.66 (8.28 to 11.27) 66 3498 45.7 (39.1 to 53.3) 38.50 (30.13 to 49.18)
Cerebral palsy
 No 63 865 6 294 857 10.1 (10.1 to 10.2) Reference 20 030 6 302 862 10.1 (10.1 to 10.2) Reference
 Yes 192 8,090 23.7 (20.6 to 27.3) 4.23 (3.67 to 4.87) 34 8116 23.7 (20.6 to 27.3) 4.40 (3.14 to 6.17)
Wave 2: children (<16 years)
Learning disability register
 No 509 1 137 827 0.4 (0.4 to 0.5) Reference —‡ —‡ —‡ —‡
 Yes 20 4152 4.8 (3.1 to 7.5) 9.18 (5.89 to 14.29) —‡ —‡ —‡ —‡
Wave 1: 1 March 2020-31 August 2020; wave 2: 1 September 2020-8 February 2021.
* Per 1000 person years.
† Rounded to avoid inadvertent disclosure of small event numbers. Median person years (25th-75th percentile): 0.504 (0.504 to 0.504) in wave 1 and 0.44 (0.44 to 0.44) in wave 2 for children 
and adults.
‡ Insufficient events for analysis.
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health record system,37 and so the population might 
not be fully nationally representative, although it 
is broadly representative in terms of ethnicity and 
deprivation.12 Identifying everyone with a learning 
disability from medical records alone was not possible. 
For instance, the most recent data, from 2015, 
suggest that 23% of people with learning disability 
are included on registers.1 The overall proportion of 
people on the learning disability register was 0.44% 
for England in 2015, slightly lower than the proportion 
in our study (0.63%); this potentially indicates an 
increase in coverage of the register in recent years. The 
reasons for under registration are unclear, but might 
include lack of perceived need and fear of stigma, 
among patients or clinicians. People on the learning 
disability register probably have more profound 
impairment and health conditions. For instance, in the 
current analyses 89% of people with Down’s syndrome 
were on the register and had higher mortality rates 
than people with Down’s syndrome who were not on 
the register. As a consequence, the hazard ratios might 
have been overestimated, although most of our sample 
had mild to moderate learning disability. Validation 
studies are not available for the Down’s syndrome and 
cerebral palsy codelists, although they were reviewed 
by clinicians specialising in the care of people with 
learning disability.
Our hospital admission data included only 
completed hospital admissions, therefore this outcome 
will have been under ascertained towards the end of 
the second wave. Defining hospital admission and 
death as covid-19 related depends on diagnosis, and 
validity of the outcome measure probably changed 
over time. If testing or clinical diagnosis of covid-19 
differed for people with learning disability compared 
with the general population, this could have biased our 
estimates in either direction. Additionally, underlying 
health conditions could have been under ascertained 
in primary care records. Data were not available for 
epilepsy, which is a covid-19 risk factor and more 
common among people with learning disability.11 13 
We also had an incomplete, and probably under-
estimated, measure of residential care.16 38
The consequences of do not resuscitate orders on the 
survival of people with learning disability have been 
raised as an area of concern, but we were not able to 
assess this impact in the current analyses. We did not 
have data on quality of treatment and so were not able to 
explore all our hypothesised pathways between learning 
disability and adverse covid-19 outcomes. Furthermore, 
these analyses focused only on severe covid-19 
outcomes, and did not explore impacts on physical 
and mental health of people with learning disability, 
which probably occurred as a result of lockdown and 
other restrictions32 and require mitigation. We focused 
on the general population and so our analyses explored 
the combination of infection and severe outcomes 
once infected, therefore we were unable to disentangle 
associations with those two steps in the process. 
However, focusing on infected people only would 
induce biases due to unrepresentative testing.
Policy implications and interpretation
In February 2021, the Joint Committee on Vaccination 
and Immunisation updated its guidance36 on which 
groups should be prioritised for vaccination. The existing 
priority groups, including those with Down’s syndrome, 
cerebral palsy or severe or profound learn ing disability, 
were extended to include all people on the learning 
disability register. This change was informed by a previ-
ous version of this analysis, which showed increased risk 
in people on the learning disability who were not already 
prioritised for vaccination. However, the current learning 
disability registers are incomplete,1 and updating them 
would help to inform prioritisation programmes. Relying 
on codelists as an alternative to learning disability 
registers is not pragmatic for prioritisation given the 
large number of codes that are non-specific for learning 
disability. Many other countries (eg, Germany39 and the 
US40) currently focus on prioritising people living in care 
homes and those with Down’s syndrome for vaccination, 
and should consider broadening this category to include 
other people with learning disability. Increased risks 
among children <16 years suggest that vaccination in 
this age group warrants further consideration. These 
data should also be used to inform future prioritisation 
for subsequent vaccination initiatives in England, and 
international vaccine prioritisation programmes. Besides 
vaccination, efforts should continue to protect people 
with learning disability from covid-19 adverse outcomes, 
including consideration of non-pharmacological 
interventions such as shielding, and ensuring adequate 
support to obtain prompt access to testing for covid-19 
and to appropriate healthcare.
Future research
The ONS data show that people with disabilities 
in general are at higher risk of covid-19 related 
mortality,41 but this outcome has not been explored 
through clinical databases, partly because of the 
complexity of generating codelists for broad ranges of 
conditions. However, using learning disability register 
data has highlighted the importance of public health 
surveillance and the need to develop indicators for 
disability. We used an indicator of care home residence 
to explore the extent to which this factor might mediate 
the association between learning disability and 
covid-19, but more detailed and accurate information 
on care home residence status is needed to understand 
how best to mitigate risk for people in residential care. 
More research is warranted on the excess covid-19 
risks among people with Down’s syndrome. Cerebral 
palsy includes people with a broad range of conditions 
and severity, and a deeper exploration of covid-19 risk 
for this group is needed.
Conclusion
People with learning disabilities have markedly 
increased risks of hospital admission and death 
from covid-19. Prompt access to covid-19 testing 
and healthcare is warranted for this group, and 
prioritisation for covid-19 vaccination and other 
targeted preventive measures should be considered.
RESEARCH
the bmj | BMJ 2021;374:n1592 | doi: 10.1136/bmj.n1592 11
This work uses data provided by patients and collected by the NHS as 
part of their care and support (http://www.usemydata.org/). We are 
grateful for all the support received from the TPP technical operations 
team throughout this work, and for generous assistance from the 
information governance and database teams at NHS England and 
NHSX. We are grateful to Rose Almond, Cally Tann, and Michelle Heys 
for their review of codelists for learning disability, Down’s syndrome, 
and cerebral palsy.
Contributors: BG conceived the platform and the approach; BG and 
LS led the project overall and are guarantors. Contributions are as 
follows: design, EJW, HIM, HK, SJWE; data curation: CB, JP, JC, SH, SB, 
DE, PI, CEM; analysis, EJW, KB, AJW, CEM; funding acquisition: BG, 
LS; information governance: AM, BG, CB, JP; methodology: EJW, HIM, 
HK, SJWE, KB, AJW, BG, LS, CB, JP, JC, SH, SB, DE, PI, CEM; disease 
category conceptualisation and codelists: CEM, AJW, PI, SB, DE, CB, 
JC, JP, SH, HJC, KB, SB, AM, BM, LT, IJD, HIM, RM, HF; ethics approval: 
HJC, EJW, LS, BG; project administration: CEM, HJC, CB, SB, AM, LS, BG; 
resources: BG, LS, FH; software: SB, DE, PI, AJW, CEM, SD, CB, FH, JC, 
SH; supervision: BG, LS, SB; writing (original draft): EJW, HK, HIM, SJWE. 
All authors were involved in design and conceptual development 
and reviewed and approved the final manuscript. The corresponding 
author attests that all listed authors meet authorship criteria and that 
no others meeting the criteria have been omitted. LS, BG and HK are 
joint principal investigators; EJW and HIM are joint first authors.
Funding: This work was supported by the Medical Research Council 
(MRC) grant MR/V015737/1. TPP provided technical expertise and 
infrastructure within their data centre pro bono in the context of a 
national emergency. EJW was supported by MRC project grant MR/
S01442X/1. HIM and MR are funded by the National Institute for 
Health Research (NIHR) Health Protection Research Unit in Vaccines 
and Immunisation, a partnership between Public Health England 
and the London School of Hygiene and Tropical Medicine. HK was 
supported by funding from the PENDA grant from the Foreign, 
Commonwealth and Development Office. BG’s work on better use 
of data in healthcare more broadly is currently funded in part by 
National Institute for Health Research (NIHR) Oxford Biomedical 
Research Centre, NIHR Applied Research Collaboration Oxford and 
Thames Valley, the Mohn-Westlake Foundation, NHS England, and 
the Health Foundation; all DataLab staff are supported by BG’s grants 
on this work. The views expressed are those of the authors and not 
necessarily those of the NIHR, NHS England, Public Health England 
or the Department of Health and Social Care. Funders had no role in 
the study design, collection, analysis, and interpretation of data; in 
the writing of the report; and in the decision to submit the article for 
publication.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare 
the following: support from the Medical Research Council, TPP, 
NIHR Oxford Biomedical Research Centre, NIHR Applied Research 
Collaboration Oxford and Thames Valley, Mohn-Westlake Foundation, 
NHS England, NIHR Health Protection Research Unit in Vaccines and 
Immunisation, the Foreign, Commonwealth and Development Office, 
and the Health Foundation for the submitted work. EJW has received 
payments from AstraZeneca for providing training, unrelated to the 
submitted work. BG has received research funding from the Laura 
and John Arnold Foundation, the NHS National Institute for Health 
Research (NIHR), the NIHR School of Primary Care Research, the NIHR 
Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, 
NIHR Applied Research Collaboration Oxford and Thames Valley, 
the Wellcome Trust, the Good Thinking Foundation, Health Data 
Research UK (HDRUK), the Health Foundation, and the World Health 
Organization; he also receives personal income from speaking and 
writing for lay audiences on the misuse of science. IJD has received 
unrestricted research grants and holds shares in GlaxoSmithKline 
(GSK) and holds grants from NIHR. LS reports grants from Wellcome, 
MRC, NIHR, UK Research and Innovation (UKRI), British Council, GSK, 
British Heart Foundation, and Diabetes UK outside this work. AS is 
employed by the London School of Hygiene and Tropical Medicine 
(LSHTM) on a fellowship sponsored by GSK. KB holds a Sir Henry 
Dale fellowship jointly funded by Wellcome and the Royal Society. 
AYSW holds a fellowship from BHF. RM holds a Sir Henry Wellcome 
Fellowship funded by the Wellcome Trust. HF holds a UKRI fellowship. 
RME is funded by HDRUK and the MRC. 
Ethical approval: This study was approved by the Health Research 
Authority (REC reference 20/LO/0651) and by the LSHTM Ethics 
Board (reference 21863).
Data sharing: All data were linked, stored and analysed securely 
within the OpenSAFELY platform (https://opensafely.org/). Data 
include pseudonymised data such as coded diagnoses, drugs, and 
physiological parameters. No free text data are included. All code is 
shared openly for review and reuse under MIT open license (https://
github.com/opensafely/absolute-risks-covid-research). Detailed 
pseudonymised patient data are potentially reidentifiable and 
therefore not shared. We rapidly delivered the OpenSAFELY data 
analysis platform without prior funding to deliver timely analyses on 
urgent research questions in the context of the global covid-19 health 
emergency: now that the platform is established we are developing 
a formal process for external users to request access in collaboration 
with NHS England; details of this process will be published shortly on 
https://opensafely.org/.
Information governance: NHS England is the data controller; TPP 
is the data processor; and the key researchers on OpenSAFELY 
are acting on behalf of NHS England. This implementation of 
OpenSAFELY is hosted within the TPP environment which is accredited 
to the ISO 27001 information security standard and is NHS IG 
Toolkit compliant42 43; patient data have been pseudonymised for 
analysis and linkage using industry standard cryptographic hashing 
techniques; all pseudonymised datasets transmitted for linkage 
onto OpenSAFELY are encrypted; access to the platform is through a 
virtual private network (VPN) connection, restricted to a small group 
of researchers; the researchers hold contracts with NHS England and 
only access the platform to initiate database queries and statistical 
models; all database activity is logged; only aggregate statistical 
outputs leave the platform environment following best practice for 
anonymisation of results such as statistical disclosure control for 
low cell counts.44 The OpenSAFELY research platform adheres to the 
obligations of the UK General Data Protection Regulation (GDPR) 
and the Data Protection Act 2018. In March 2020, the Secretary of 
State for Health and Social Care used powers under the UK Health 
Service (Control of Patient Information) Regulations 2002 (COPI) to 
require organisations to process confidential patient information 
for the purposes of protecting public health, providing healthcare 
services to the public and monitoring and managing the covid-19 
outbreak and incidents of exposure; this sets aside the requirement 
for patient consent.45 Taken together, these provide the legal bases 
to link patient datasets on the OpenSAFELY platform. GP practices, 
from which the primary care data are obtained, are required to share 
relevant health information to support the public health response to 
the pandemic, and have been informed of the OpenSAFELY analytics 
platform.
The lead authors (BG and LS) affirm that the manuscript is an honest, 
accurate, and transparent account of the study being reported; that 
no important aspects of the study have been omitted; and that any 
discrepancies from the study as planned (and, if relevant, registered) 
have been explained.
Dissemination to participants and related patient and public 
communities: Dissemination of findings will be undertaken through 
a variety of routes. A lay summary and Easyread summary aimed 
at people with learning disability will be made available on the 
OpenSAFELY and HPRU in Vaccines and Immunisation websites 
(https://opensafely.org/ and https://immunisation.hpru.nihr.ac.uk/).
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